Company research
ZYNEX INC
CIK 846475Updated Sep 26, 2026
Securities
Historical securities (2)
ZYXIQ · OTC · equity · closed Mar 26, 2026ZYXI · NYSE_AMERICAN · equity · closed Dec 23, 2025Name history
ZYNEX MEDICAL HOLDINGS INC · through Jul 8, 2008ZYNEX MEDICAL HOLDINGS INC · through Aug 12, 2005FOX RIVER HOLDINGS INC · through Jan 20, 2004ARIZONA VENTURES INC · through Aug 19, 2003CHINA GLOBAL DEVELOPMENT INC · through Jan 15, 2003IBONZAI COM INC · through Jun 12, 2001LIFE MEDICAL TECHNOLOGIES INC /UT/ · through May 25, 2000
ZYXIQ price & chart
Historical security
This listing closed Mar 26, 2026. Live provider charts are shown only for current listings.
About the company
Zynex, founded in 1996, is a pain management device manufacturer and distributor. For additional information, visit: www.zynex.com.
In the news
Recent filings
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 1.02, 2.03, 3.02, 3.03, 5.01, 5.02, 5.03, 9.01
15-12G filing
S-8 POS filing
S-8 POS filing
Bankruptcy or Receivership
Items 1.03, 9.01
Show 5 more recent filings
EFFECT filing
RW filing
POS AM filing
Other Events
Items 8.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 122,079,000Source | 136,904,000Source | 116,466,000Source | 133,274,000Source |
| Property, Plant and Equipment, NetUSD | 3,084,000Source | 3,114,000Source | 2,175,000Source | 2,186,000Source |
| GoodwillUSD | 20,401,000Source | 20,401,000Source | 20,401,000Source | 20,401,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,247,000Source | 8,158,000Source | 9,067,000Source | 9,975,000Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 18,022,000Source | 26,838,000Source | 35,063,000Source | 28,632,000Source |
| Inventory, NetUSD | 13,919,000Source | 13,106,000Source | 13,484,000Source | 10,756,000Source |
| Assets, CurrentUSD | 75,179,000Source | 87,855,000Source | 69,559,000Source | 82,689,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,607,000Source | 3,332,000Source | 868,000Source | 689,000Source |
| Operating Lease, Right-of-Use AssetUSD | 9,820,000Source | 12,515,000Source | 12,841,000Source | 16,338,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 86,371,000Source | 90,775,000Source | 50,108,000Source | 59,349,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 32,000Source | 33,000Source | 39,000Source | 41,000Source |
| Retained Earnings (Accumulated Deficit)USD | 29,774,000Source | 26,780,000Source | 17,048,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 35,708,000Source | 46,129,000Source | 66,358,000Source | 73,925,000Source |
| Additional Paid in Capital, Common StockUSD | 93,088,000Source | 90,878,000Source | 82,431,000Source | 80,397,000Source |
| Liabilities and EquityUSD | 122,079,000Source | 136,904,000Source | 116,466,000Source | 133,274,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,864,000Source | 18,532,000Source | 21,086,000Source | 22,871,000Source |
| Operating Lease, Liability, CurrentUSD | 4,030,000Source | 3,729,000Source | 2,476,000Source | 2,859,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,151,000Source | 14,181,000Source | 13,541,000Source | 15,856,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 4,026,000Source | 4,170,000Source | 3,884,000Source | 4,806,000Source |
| Dividends Payable, CurrentUSD | — | — | 16,000Source | 3,629,000Source |
| Dividends PayableUSD | — | — | — | 3,622,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 5,293,000Source | 10,605,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 5,333,000Source | 5,333,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 5,293,000Source | 10,605,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 2,994,000Source | 9,732,000Source | 17,048,000Source | 17,103,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,989,000Source | 2,296,000Source | 2,342,000Source | 1,630,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -8,816,000Source | -8,225,000Source | 6,430,000Source | 14,781,000Source |
| Increase (Decrease) in InventoriesUSD | 2,736,000Source | 1,445,000Source | 4,320,000Source | 3,776,000Source |
| Deferred Income Tax Expense (Benefit)USD | -934,000Source | -2,303,000Source | -851,000Source | -146,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 12,721,000Source | 17,756,000Source | 13,746,000Source | 6,949,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | 15,997,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -578,000Source | -966,000Source | -418,000Source | -16,606,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 578,000Source | 1,206,000Source | 418,000Source | 609,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 672,000Source | 737,000Source | 352,000Source | 236,000Source |
| Payments for Repurchase of Common StockUSD | 15,625,000Source | 37,924,000Source | 26,426,000Source | 2,667,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -17,091,000Source | 7,645,000Source | -35,796,000Source | 13,096,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 9,000Source | 3,000Source | 3,613,000Source | 1,000Source |
| Repayments of Long-term DebtUSD | — | 10,667,000Source | 5,333,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -4,948,000Source | 24,435,000Source | -22,468,000Source | 3,439,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 39,631,000Source | 44,579,000Source | 20,144,000Source | 42,612,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 739,000Source | 391,000Source | 82,000Source |
| Income Taxes Paid, NetUSD | -2,582,000Source | -6,456,000Source | -6,294,000Source | -3,305,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,989,000Source | 2,296,000Source | 2,342,000Source | 1,630,000Source |
| Amortization of Intangible AssetsUSD | 1,881,000Source | 1,536,000Source | 930,000Source | 25,000Source |
| DepreciationUSD | 2,901,000Source | 2,684,000Source | 2,197,000Source | 2,261,000Source |
| Dividends Payable, CurrentUSD | — | — | 16,000Source | 3,629,000Source |
| Dividends PayableUSD | — | — | — | 3,622,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 19,000Source | 39,000Source | — | — |
| General and Administrative ExpenseUSD | 60,354,000Source | 48,517,000Source | 36,108,000Source | 26,324,000Source |
| GoodwillUSD | 20,401,000Source | 20,401,000Source | 20,401,000Source | 20,401,000Source |
| Income Tax Expense (Benefit)USD | 633,000Source | 2,847,000Source | 5,150,000Source | 5,168,000Source |
| Net Income (Loss) Attributable to ParentUSD | 2,994,000Source | 9,732,000Source | 17,048,000Source | 17,103,000Source |
| Nonoperating Income (Expense)USD | -2,363,000Source | 1,799,000Source | -740,000Source | -95,000Source |
| Proceeds from Stock Options ExercisedUSD | 100,000Source | 100,000Source | 100,000Source | 200,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 192,354,000Source | 184,322,000Source | 158,167,000Source | 130,301,000Source |
| Cost of RevenueUSD | 39,429,000Source | 38,366,000Source | 32,005,000Source | 27,321,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | 5,990,000Source | 10,780,000Source | 22,938,000Source | 22,366,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 3,627,000Source | 12,579,000Source | 22,198,000Source | 22,271,000Source |
| Income Tax Expense (Benefit)USD | 633,000Source | 2,847,000Source | 5,150,000Source | 5,168,000Source |
| Net Income (Loss) Attributable to ParentUSD | 2,994,000Source | 9,732,000Source | 17,048,000Source | 17,103,000Source |
| Earnings Per Share, BasicUSD per share | 0.09Source | 0.27Source | 0.44Source | 0.45Source |
| Earnings Per Share, DilutedUSD per share | 0.09Source | 0.27Source | 0.44Source | 0.44Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 31,941,000Source | 35,555,000Source | 38,467,000Source | 38,317,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,299,000Source | 36,142,000Source | 39,127,000Source | 39,197,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,881,000Source | 1,536,000Source | 930,000Source | 25,000Source |
| Costs and ExpensesUSD | 186,364,000Source | 173,542,000Source | 135,229,000Source | 107,935,000Source |
| Current Income Tax Expense (Benefit)USD | 1,567,000Source | 5,150,000Source | 6,001,000Source | 5,314,000Source |
| General and Administrative ExpenseUSD | 60,354,000Source | 48,517,000Source | 36,108,000Source | 26,324,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 3,627,000Source | 12,579,000Source | 22,220,000Source | 22,295,000Source |
| Interest Income (Expense), NetUSD | — | -1,094,000Source | -440,000Source | -95,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -2,382,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,363,000Source | 1,799,000Source | -740,000Source | -95,000Source |
| Research and Development ExpenseUSD | 12,000,000Source | 9,200,000Source | 7,100,000Source | 2,600,000Source |
| Selling and Marketing ExpenseUSD | 86,581,000Source | 86,659,000Source | 67,116,000Source | 54,290,000Source |
Filing attachments
zyxi-20260217xex99d1.htm · 8-K · 2026-02-18
EX-99.1 3 zyxi-20260217xex99d1.htm EX-99.1 Exhibit 99.1 Zynex Poised for New Future with Resolution of Federal Investigation ENGLEWOOD, Colo., Feb. 17, 2026 - Zynex, Inc., today announced that it has resolved the federal government’s investigation into business practices designed and implemented by the company’s former executives. Under the non-prosecution agreement (NPA) signed today, the United States Attorney’s Office for the District of Rhode Island (USAO RI) has agreed not to pursue c…
Read attachment ↗zyxi-20260122xex99d1.htm · 8-K · 2026-01-23
EX-99.1 2 zyxi-20260122xex99d1.htm EX-99.1 Exhibit 99.1 New Zynex Leadership Responds to Indictment of Former Executives ENGLEWOOD, Colo., Jan. 22, 2026 - Zynex, Inc. (ZYXIQ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today issued the following statement regarding the federal indictments of two former executives. “Zynex, Inc. is aware of the federal indictments of two former exe…
Read attachment ↗zyxi-20251215xex99d1.htm · 8-K · 2025-12-16
EX-99.1 3 zyxi-20251215xex99d1.htm EX-99.1 Exhibit 99.1 Zynex Financial Restructuring Puts Company on Path to Long-Term Success ENGLEWOOD, Colo., Dec. 16, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation today announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring with the support of new financing from the Compan…
Read attachment ↗zyxi-20251215xex99d2.htm · 8-K · 2025-12-16
EX-99.2 4 zyxi-20251215xex99d2.htm EX-99.2 Exhibit 99.2 NASDAQ: ZYXI Discussion Materials November 13, 2025 ──────────────────────── NASDAQ: ZYXI Disclaimer The purpose of this presentation (the “Presentation”) is to introduce the reader to Zynex, Inc. (“Zynex” or the “Company”) and Province, LLC (“Province”). This Presentation is being made available only to parties who have signed and returned a Confidentiality Agreement. Recipients agree to use and maintain the informatio…
Read attachment ↗zyxi-20250818xex99d1.htm · 8-K · 2025-08-20
EX-99.1 2 zyxi-20250818xex99d1.htm EX-99.1 Exhibit 99.1 Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles ENGLEWOOD, Colo., August 18, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new lea…
Read attachment ↗zyxi-20250731xex99d1.htm · 8-K · 2025-07-31
EX-99.1 2 zyxi-20250731xex99d1.htm EX-99.1 Exhibit 99.1 Zynex Reports Second Quarter 2025 Financial Results ENGLEWOOD, Colo., July 31, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary “In the second quarter of 2…
Read attachment ↗